HALO Share Price

Open 13.58 Change Price %
High 13.79 1 Day 0.07 0.52
Low 13.40 1 Week 0.27 2.04
Close 13.53 1 Month -0.46 -3.29
Volume 504253 1 Year 3.60 36.25
52 Week High 15.20
52 Week Low 8.18
HALO Important Levels
Resistance 2 13.89
Resistance 1 13.74
Pivot 13.57
Support 1 13.32
Support 2 13.17
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
DCTH 0.14 -6.67%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPSL 0.14 55.56%
LOCM 0.09 50.00%
HAUP 0.10 42.86%
SYMX 0.50 38.89%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPNT 11.40 24.73%
IFON 0.61 24.49%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DCIX 0.19 -58.70%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Halozyme Therapeutics, Inc. (NASDAQ: HALO)

HALO Technical Analysis 3
As on 26th Jul 2017 HALO Share Price closed @ 13.53 and we RECOMMEND Buy for LONG-TERM with Stoploss of 12.22 & Buy for SHORT-TERM with Stoploss of 13.31 we also expect STOCK to react on Following IMPORTANT LEVELS.
HALO Target for July
1st Target up-side 14.57
2nd Target up-side 15.8
3rd Target up-side 17.02
1st Target down-side 11.07
2nd Target down-side 9.84
3rd Target down-side 8.62
HALO Other Details
Segment EQ
Market Capital 613046848.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.halozyme.com
HALO Address
HALO
11388 Sorrento Valley Road
San Diego, CA 92121
United States
Phone: 858-794-8889
Fax: 858-704-8311
HALO Latest News
Interactive Technical Analysis Chart Halozyme Therapeutics, Inc. ( HALO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Halozyme Therapeutics, Inc.
HALO Business Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company�s research focuses primarily on human enzymes that alter the extracellular matrix. The Company�s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates.